Chief Executive Officer · Grace Therapeutics, Inc. (GRCE)

Prashant Kohli

A named executive officer of Grace Therapeutics in every fiscal year CompBrief holds from FY2025 to FY2026. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2026

$1,270,820

Salary $579,000Stock awards $0

FY2025: $1,084,971

1st of 3 named executive officers at Grace Therapeutics by FY2026 total.

3 named officers on file for Grace Therapeutics, FY2026

Prashant Kohli’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Grace Therapeutics’s whole pay program stands against its peers

  • Grace Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on GRCE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed July 28, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Prashant Kohli’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Prashant Kohli compensation by year

Grace Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Grace Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025FY2026
Salary$500,000$579,000
Bonus$0$0
Stock awards$0$0
Option awards$324,621$391,820
Non-equity incentive$250,000$289,500
Pension and deferred compensation$0$0
All other$10,350$10,500
Total$1,084,971$1,270,820

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Grace Therapeutics, Inc. DEF 14A filed July 28, 2026, accession 0001140361-26-029889, and prior-year filings.

How this page was built: the Grace Therapeutics, Inc. filed document, accession 0001140361-26-029889. Every figure is read from that document and cited to the page and table it appears in. Filed July 28, 2026.

$1.1M
$1.3M
FY25
FY26
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2026 year-end
TypeUnvested unitsValue at year-endExercise price
Option169,051—$2.08
Option17,361—$2.64
Option53,654—$2.96

Per the Outstanding Equity Awards at Fiscal Year-End table in Grace Therapeutics, Inc.'s FY2026 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

2 Form 4 lines since the FY2026 proxy (filed July 28, 2026)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-09-09Purchase—100,000$2.14121,357
2026-08-28Grant or award derivative—267,160$0.00267,160

The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Grace Therapeutics’s named executive officers, FY2026

as the company reported each
Named executive officerRoleFY2026 total
Prashant Kohli · this pageChief Executive Officer$1,270,820
Amresh KumarVice President, Program Management$465,650
Carrie D’AndreaFormer Vice President, Clinical Operations$465,650

The full Grace Therapeutics compensation record

free company brief

This page is one person within Grace Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Grace Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Prashant Kohli's compensation dossier · One-time report. No refunds.